Alprostadil detailed information

(Redirected from Alprostadil)
Jump to: navigation, search
Alprostadil detailed information
Systematic (IUPAC) name
7-[3-hydroxy-2-(3-hydroxyoct-1-enyl)- 5-oxo-cyclopentyl] heptanoic acid
Identifiers
CAS number 745-65-3
ATC code C01EA01 G04BE01
PubChem 149351
DrugBank APRD00785
Chemical data
Formula C20H34O5 
Mol. mass 354.481 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

WikiDoc Resources for

Alprostadil detailed information

Articles

Most recent articles on Alprostadil detailed information

Most cited articles on Alprostadil detailed information

Review articles on Alprostadil detailed information

Articles on Alprostadil detailed information in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Alprostadil detailed information

Images of Alprostadil detailed information

Photos of Alprostadil detailed information

Podcasts & MP3s on Alprostadil detailed information

Videos on Alprostadil detailed information

Evidence Based Medicine

Cochrane Collaboration on Alprostadil detailed information

Bandolier on Alprostadil detailed information

TRIP on Alprostadil detailed information

Clinical Trials

Ongoing Trials on Alprostadil detailed information at Clinical Trials.gov

Trial results on Alprostadil detailed information

Clinical Trials on Alprostadil detailed information at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Alprostadil detailed information

NICE Guidance on Alprostadil detailed information

NHS PRODIGY Guidance

FDA on Alprostadil detailed information

CDC on Alprostadil detailed information

Books

Books on Alprostadil detailed information

News

Alprostadil detailed information in the news

Be alerted to news on Alprostadil detailed information

News trends on Alprostadil detailed information

Commentary

Blogs on Alprostadil detailed information

Definitions

Definitions of Alprostadil detailed information

Patient Resources / Community

Patient resources on Alprostadil detailed information

Discussion groups on Alprostadil detailed information

Patient Handouts on Alprostadil detailed information

Directions to Hospitals Treating Alprostadil detailed information

Risk calculators and risk factors for Alprostadil detailed information

Healthcare Provider Resources

Symptoms of Alprostadil detailed information

Causes & Risk Factors for Alprostadil detailed information

Diagnostic studies for Alprostadil detailed information

Treatment of Alprostadil detailed information

Continuing Medical Education (CME)

CME Programs on Alprostadil detailed information

International

Alprostadil detailed information en Espanol

Alprostadil detailed information en Francais

Business

Alprostadil detailed information in the Marketplace

Patents on Alprostadil detailed information

Experimental / Informatics

List of terms related to Alprostadil detailed information

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Alprostadil is the pharmaceutical name for prostaglandin E1. It is used as a drug in the treatment of erectile dysfunction and has vasodilatory properties.[1]

Sexual dysfunction

Aprostidil is sold in the United States under the brand name Muse.[2] It is also sold as Caverject and Edex.

Muse delivers alprostadil as a penile suppository, inserted into the urethra, at least ten minutes before the erection will be needed. Caverject and Edex are similarly fast-acting, but are actually injected directly into the corpus cavernosum of the penis.

This drug is reputed to work for erectile dysfunction for 30 to 60 minutes.

This drug, following on the coattails of Viagra, has failed to achieve comparable above-ground market share in the United States, perhaps in part because of the invasive means of delivery.

NexMed is developing transdermal forumulations—Alprox-TD(R) for men with erectile dysfunction and Femprox(R) for female sexual arousal disorder. Alprox-TD(R) has been selling in China and in Hong Kong since October 2001 and April 2002, respectively. Two Phase III studies have been completed for this product, and the Company is seeking regulatory approval in the U.S., Canada and Europe. [3]

Other uses

Aprostadil is also used in maintaining a patent ductus arteriosus in the fetus. This is primarily useful when there is threat of premature closure of the ductus arteriosus.[1]

References

  1. 1.0 1.1 a_26/12123006 at Dorland's Medical Dictionary
  2. Muse.
  3. Fain Hughes (2007-10-29). NEXM: Dutton Sees Strong Speculative Buy and 12-Month Price Double. Retrieved on 2007-11-01.



Navigation WikiDoc | WikiPatient | Popular pages | Recently Edited Pages | Recently Added Pictures

Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs

Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link Here
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
Linked-in.jpg
Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox
In other languages